BioXcel Therapeutics Management
Management criteria checks 3/4
BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 6.92 years. total yearly compensation is $4.56M, comprised of 20.7% salary and 79.3% bonuses, including company stock and options. directly owns 0.12% of the company’s shares, worth €115.11K. The average tenure of the management team and the board of directors is 4.9 years and 5.8 years respectively.
Key information
Vimal Mehta
Chief executive officer
US$4.6m
Total compensation
| CEO salary percentage | 20.7% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.1% |
| Management average tenure | 4.9yrs |
| Board average tenure | 5.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -US$179m |
| Sep 30 2023 | n/a | n/a | -US$212m |
| Jun 30 2023 | n/a | n/a | -US$203m |
| Mar 31 2023 | n/a | n/a | -US$187m |
| Dec 31 2022 | US$5m | US$944k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$137m |
| Jun 30 2022 | n/a | n/a | -US$122m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$9m | US$917k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$100m |
| Mar 31 2021 | n/a | n/a | -US$94m |
| Dec 31 2020 | US$10m | US$890k | -US$82m |
| Sep 30 2020 | n/a | n/a | -US$69m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$459k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$702k | US$423k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$15m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$284k | US$147k | -US$5m |
Compensation vs Market: Vimal's total compensation ($USD4.56M) is above average for companies of similar size in the German market ($USD406.04K).
Compensation vs Earnings: Vimal's compensation has been consistent with company performance over the past year.
CEO
Vimal Mehta (61 yo)
6.9yrs
Tenure
US$4,559,195
Compensation
Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 6.9yrs | US$4.56m | 0.12% $ 115.1k | |
| Senior VP | 3.3yrs | US$1.22m | 0.021% $ 19.4k | |
| Senior VP & Chief Commercial Officer | 2.3yrs | US$1.93m | 0.0054% $ 5.0k | |
| Senior VP & CFO | 6.5yrs | US$404.00k | 0.013% $ 12.0k | |
| Senior VP & Chief Scientific Officer | 6.8yrs | US$1.15m | 0.034% $ 32.2k | |
| Executive VP and Chief of Product Development & Medical Officer | 6.8yrs | US$510.17k | 0.015% $ 13.7k | |
| Senior VP and Head of Translational Medicine | 1.8yrs | no data | no data | |
| Chief Medical Officer - Neuroscience | 2.3yrs | no data | no data |
4.9yrs
Average Tenure
57.5yo
Average Age
Experienced Management: BX2's management team is considered experienced (4.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7yrs | US$4.56m | 0.12% $ 115.1k | |
| Member of Advisory Board | no data | no data | no data | |
| Independent Chairman & Lead Director | 7yrs | US$295.17k | 0.63% $ 587.6k | |
| Member of Clinical Advisory Board | 5.8yrs | no data | no data | |
| Member of Clinical Advisory Board | 5.2yrs | no data | no data | |
| Member of Clinical Advisory Board | 5.2yrs | no data | no data | |
| Member of Clinical Advisory Board | 5.8yrs | no data | no data | |
| Member of Clinical Advisory Board | 5.8yrs | no data | no data | |
| Member of Clinical Advisory Board | 5.2yrs | no data | no data | |
| Director | no data | US$264.62k | 0% $ 0 | |
| Member of Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 5.8yrs | no data | no data |
5.8yrs
Average Tenure
61yo
Average Age
Experienced Board: BX2's board of directors are considered experienced (5.8 years average tenure).